Taraxasterol Suppresses Renal Cell Carcinoma Progression by Modulating Cell Cycle Progression and Apoptosis

Area of Science:

• Pharmacology
• Oncology
• Natural Products Chemistry

Background:

• Renal cell carcinoma (RCC) is an aggressive cancer with limited treatment options.
• Natural compounds are being explored for their therapeutic potential in cancer treatment.
• Taraxasterol (TAX), a triterpene from dandelion, has shown antitumor activity but its role in RCC was unknown.

Purpose of the Study:

• To investigate the antitumor effects of Taraxasterol (TAX) on renal cell carcinoma (RCC) cells.
• To elucidate the underlying molecular mechanisms of TAX's action in RCC.
• To evaluate the efficacy of TAX in a preclinical in vivo model of RCC.

Main Methods:

• In vitro studies utilized MTT assay, scratch, Transwell assays, flow cytometry, and Western blotting on RCC cells.
• In vivo efficacy was assessed using a 786-O xenograft mouse model.
• Analysis included cell viability, proliferation, migration, invasion, apoptosis, cell cycle, mitochondrial membrane potential, and protein expression.

Main Results:

• TAX demonstrated significant antiproliferative, anti-migratory, and anti-invasive effects on 786-O RCC cells without affecting normal kidney cells.
• TAX induced apoptosis and G2/M cell cycle arrest, reduced mitochondrial membrane potential, and modulated key proteins involved in apoptosis and cell cycle regulation.
• In vivo, TAX suppressed tumor growth, reduced proliferation marker Ki-67, and increased apoptosis marker cleaved Caspase-3 in xenograft tumors.

Conclusions:

• Taraxasterol (TAX) exhibits potent antiproliferative, pro-apoptotic, and anti-invasive properties against renal cell carcinoma (RCC).
• TAX demonstrates significant potential as a therapeutic candidate for RCC treatment.
• Further research is warranted to explore TAX's efficacy in diverse RCC models and its broader molecular pathways.